衰老影响甲状腺癌发生发展的机制研究进展

doi:10.3969/j.issn.1004-616x.2025.04.012

摘要/Abstract

摘要： 在全球人口老龄化趋势加速的背景下，衰老与肿瘤发生发展的关联性正成为研究热点。大量临床及基础研究证实，衰老进程中的生物学改变与肿瘤发生存在显著相关性。例如衰老细胞的积累会导致慢性炎症和免疫功能障碍，从而为肿瘤的发展创造有利条件。此外衰老细胞通过分泌衰老相关的分泌表型(SASP)复合物，对肿瘤微环境产生多重影响。值得注意的是，在现行肿瘤分期体系中，甲状腺癌是唯一将患者年龄作为核心预后评估指标和分期依据的恶性肿瘤类型。研究表明，甲状腺癌的恶性风险与年龄密切相关，年龄较大的患者往往表现出更高的恶性程度和更复杂的肿瘤特征。因此，深入探讨衰老微环境对甲状腺癌发生发展的调控机制，不仅有助于揭示年龄相关肿瘤演进的特殊规律，更能为甲状腺癌的三级预防体系构建即病因预防、早期筛查及恶性进展阻断提供关键理论依据。这具有转化医学和精准医学的双重价值，为未来开发针对衰老相关肿瘤的新型治疗策略提供了可能。

关键词: 甲状腺癌, 衰老, 肿瘤微环境, 人口老龄化, 恶性肿瘤

中图分类号:

R363.2+1

梁心恩, 肖汀, 郭会芹. 衰老影响甲状腺癌发生发展的机制研究进展[J]. 癌变·畸变·突变, 2025, 37(4): 304-307.

LIANG Xinen, XIAO Ting, GUO Huiqin. Research progress on the mechanism of aging affecting the occurrence and development of thyroid cancer[J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2025, 37(4): 304-307.

参考文献

[1] MONTéGUT L, LóPEZ-OTíN C, KROEMER G. Aging and cancer[J]. Mol Cancer, 2024, 23(1): 106.
[2] VAN HERCK Y, FEYAERTS A, ALIBHAI S, et al. Is cancer biology different in older patients-[J]. Lancet Healthy Longev, 2021, 2(10): e663-e677.
[3] AMIN M B, GREENE F L, EDGE S B, et al. The eighth edition AJCC cancer staging manual: continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging[J]. CA Cancer J Clin, 2017, 67(2): 93-99.
[4] AUNAN J R, CHO W C, SØREIDE K. The biology of aging and cancer: a brief overview of shared and divergent molecular hallmarks[J]. Aging Dis, 2017, 8(5): 628-642.
[5] WAKIYAMA H, MASUDA T, MOTOMURA Y, et al. Cytolytic activity (CYT) score is a prognostic biomarker reflecting host immune status in hepatocellular carcinoma (HCC)[J]. Anticancer Res, 2018, 38(12): 6631-6638.
[6] 姚承志, 张敏, 曾雨可, 等. 中国甲状腺癌发病和死亡趋势分析与预测[J]. 中华流行病学杂志, 2023, 44(6): 917-923.
[7] TONIATO A, BERNARDI C, PIOTTO A, et al. Features of papillary thyroid carcinoma in patients older than 75 years[J]. Updates Surg, 2011, 63(2): 115-118.
[8] GESING A, LEWI-SKI A, KARBOWNIK-LEWI-SKA M. The thyroid gland and the process of aging；what is new-[J]. Thyroid Res, 2012, 5(1): 16.
[9] KIM T Y, KIM K W, JUNG T S, et al. Prognostic factors for Korean patients with anaplastic thyroid carcinoma[J]. Head Neck, 2007, 29(8): 765-772.
[10] MINNA E, BRICH S, TODOERTI K, et al. Cancer associated fibroblasts and senescent thyroid cells in the invasive front of thyroid carcinoma[J]. Cancers (Basel), 2020, 12(1): 112.
[11] KIM Y H, CHOI Y W, LEE J, et al. Senescent tumor cells lead the collective invasion in thyroid cancer[J]. Nat Commun, 2017, 8: 15208.
[12] VAN H D. The ageing thyroid: implications for longevity and patient care[J]. Nat Rev Endocrinol, 2024, 20(1): 5-15.
[13] SAJINA Z. Role of TSH in predicting malignant thyroid tumours[J]. J Surg Res Pract, 2025: 1-5.
[14] SAKORAFAS G H, PEROS G, FARLEY D R. Thyroid nodules: does the suspicion for malignancy really justify the increased thyroidectomy rates-[J]. Surg Oncol, 2006, 15(1): 43-55.
[15] KIM T H, LEE M Y, JIN S M, et al. The association between serum concentration of thyroid hormones and thyroid cancer: a cohort study[J]. Endocr Relat Cancer, 2022, 29(12): 635-644.
[16] 梁月辉, 肖芳. 衰老相关分泌表型对恶性肿瘤的双向调节作用[J]. 中华老年医学杂志, 2020(8): 971-975.
[17] RUHLAND M K, LOZA A J, CAPIETTO A H, et al. Stromal senescence establishes an immunosuppressive microenvironment that drives tumorigenesis[J]. Nat Commun, 2016, 7: 11762.
[18] HIRATA T, ARAI Y, YUASA S, et al. Associations of cardiovascular biomarkers and plasma albumin with exceptional survival to the highest ages[J]. Nat Commun, 2020, 11(1): 3820.
[19] DEMARIA M, O’LEARY M N, CHANG J H, et al. Cellular senescence promotes adverse effects of chemotherapy and cancer relapse[J]. Cancer Discov, 2017, 7(2): 165-176.
[20] HIERONYMUS H, MURALI R, TIN A, et al. Tumor copy number alteration burden is a pan-cancer prognostic factor associated with recurrence and death[J]. eLife, 2018, 7: e37294.
[21] RUIZ E, KANDIL E, ALHASSAN S, et al. An integrative multi-omics analysis of the molecular links between aging and aggressiveness in thyroid cancers[J]. Aging Dis, 2023, 14(3): 992-1012.
[22] WREESMANN V B, SIECZKA E M, SOCCI N D, et al. Genome-wide profiling of papillary thyroid cancer identifies MUC1 as an independent prognostic marker[J]. Cancer Res, 2004, 64(11): 3780-3789.
[23] CANCER Genome Atlas Research Network. Integrated genomic characterization of papillary thyroid carcinoma[J]. Cell, 2014, 159(3): 676-690.
[24] KJELLMAN P, LAGERCRANTZ S, H--G A, et al. Gain of 1q and loss of 9q21.3-Q32 are associated with a less favorable prognosis in papillary thyroid carcinoma[J]. Genes Chromosomes Cancer, 2001, 32(1): 43-49.
[25] GIRALDO N A, SANCHEZ-SALAS R, PESKE J D, et al. The clinical role of the TME in solid cancer[J]. Br J Cancer, 2019, 120(1): 45-53.
[26] YANG Z, WEI X Y, PAN Y T, et al. A new risk factor indicator for papillary thyroid cancer based on immune infiltration[J]. Cell Death Dis, 2021, 12(1): 51.
[27] FRENCH J D, BIBLE K, SPITZWEG C, et al. Leveraging the immune system to treat advanced thyroid cancers[J]. Lancet Diabetes Endocrinol, 2017, 5(6): 469-481.
[28] QING W, FANG W Y, YE L, et al. Density of tumor-associated macrophages correlates with lymph node metastasis in papillary thyroid carcinoma[J]. Thyroid, 2012, 22(9): 905-910.
[29] KIM S, CHO S W, MIN H S, et al. The expression of tumor-associated macrophages in papillary thyroid carcinoma[J]. Endocrinol Metab (Seoul), 2013, 28(3): 192-198.
[30] RYDER M, GHOSSEIN R A, RICARTE-FILHO J C M, et al. Increased density of tumor-associated macrophages is associated with decreased survival in advanced thyroid cancer[J]. Endocr Relat Cancer, 2008, 15(4): 1069-1074.
[31] CAILLOU B, TALBOT M, WEYEMI U, et al. Tumor-associated macrophages (TAMs) form an interconnected cellular supportive network in anaplastic thyroid carcinoma[J]. PLoS One, 2011, 6(7): e22567.
[32] MAZZONI M, MAURO G, ERRENI M, et al. Senescent thyrocytes and thyroid tumor cells induce M2-like macrophage polarization of human monocytes via a PGE2-dependent mechanism[J]. J Exp Clin Cancer Res, 2019, 38(1): 208.
[33] HSIAO S J, NIKIFOROV Y E. Molecular approaches to thyroid cancer diagnosis[J]. Endocr Relat Cancer, 2014, 21(5): T301-T313.
[34] WANG T T, SHI J Y, LI L C, et al. Single-cell transcriptome analysis reveals inter-tumor heterogeneity in bilateral papillary thyroid carcinoma[J]. Front Immunol, 2022, 13: 840811.
[35] ATTIA A S, HUSSEIN M, ISSA P P, et al. Association of BRAFV600E mutation with the aggressive behavior of papillary thyroid microcarcinoma: a meta-analysis of 33 studies[J]. Int J Mol Sci, 2022, 23(24): 15626.
[36] ELISEI R, UGOLINI C, VIOLA D, et al. BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year Median follow-up study[J]. J Clin Endocrinol Metab, 2008, 93(10): 3943-3949.
[37] JIN L P, CHEN E D, DONG S Y, et al. BRAF and TERT promoter mutations in the aggressiveness of papillary thyroid carcinoma: a study of 653 patients[J]. Oncotarget, 2016, 7(14): 18346-18355.
[38] KIM S J, LEE K E, MYONG J P, et al. BRAF V600E mutation is associated with tumor aggressiveness in papillary thyroid cancer[J]. World J Surg, 2012, 36(2): 310-317.
[39] LANDA I, IBRAHIMPASIC T, BOUCAI L, et al. Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers[J]. J Clin Invest, 2016, 126(3): 1052-1066.
[40] HAN Y, XU S J, CHENG K, et al. CENPF promotes papillary thyroid cancer progression by mediating cell proliferation and apoptosis[J]. Exp Ther Med, 2021, 21(4): 401.
[41] WANG S N, WU J, GUO C C, et al. Identification and validation of novel genes in anaplastic thyroid carcinoma via bioinformatics analysis[J]. Cancer Manag Res, 2020, 12: 9787-9799.
[42] LIU M, QIU Y L, JIN T, et al. Meta-analysis of microarray datasets identify several chromosome segregation-related cancer/testis genes potentially contributing to anaplastic thyroid carcinoma[J]. PeerJ, 2018, 6: e5822.